ITGR Stock Analysis: Integer Holdings | NYSE
Medical Devices | NYSE, USA | Market Cap: 4.303m USD | 12M Return: 84.2% | US45826H1095 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 98.2M
EPS Trend: 92.5%
Qual. Beats: -1
Rev. Trend: 95.1%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Integer Holdings (NYSE: ITGR) is a U.S.-based medical device contract developer and manufacturer serving multinational medical technology companies. Its products span cardiac rhythm management, neuromodulation, cardiovascular and vascular procedures, surgery, orthopedics, and portable medical equipment.
The company supplies both finished devices and components, including implantable devices, leads, batteries, and enclosures. Its contract manufacturing model supports original equipment manufacturers across the health care equipment sector.
- Cardio and vascular device demand drives core revenue growth
- OEM program ramps and outsourcing wins shape sales visibility
- Capacity investments and manufacturing efficiencies support margin expansion
| Net Income: 103.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: 32.90% < 20% (prev 31.14%; Δ 1.77% < -1%) |
| CFO/TA 0.05 > 3% & CFO 176.5m > Net Income 103.7m |
| Net Debt (1.46b) to EBITDA (286.2m): 5.09 < 3 |
| Current Ratio: 3.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.6m) vs 12m ago -2.82% < -2% |
| Gross Margin: 23.58% > 18% (prev 24.02%; Δ -0.43% > 0.5%) |
| Asset Turnover: 53.72% > 50% (prev 53.72%; Δ 0.00% > 0%) |
| Interest Coverage Ratio: 3.78 > 6 (EBIT TTM 146.8m / Interest Expense TTM 38.8m) |
| A: 0.18 (Total Current Assets 801.4m - Total Current Liabilities 201.1m) / Total Assets 3.39b |
| B: 0.31 (Retained Earnings 1.05b / Total Assets 3.39b) |
| C: 0.04 (EBIT TTM 146.8m / Avg Total Assets 3.40b) |
| D: 1.04 (Book Value of Equity 1.73b / Total Liabilities 1.67b) |
| Altman-Z'' = 3.55 = A |
| DSRI: 0.83 (Receivables 345.1m/417.3m, Revenue 1.82b/1.83b) |
| GMI: 1.02 (GM 24.02% / 23.58%) |
| AQI: 0.97 (AQ_t 0.57 / AQ_t-1 0.58) |
| SGI: 1.00 (Revenue 1.82b / 1.83b) |
| TATA: -0.02 (NI 103.7m - CFO 176.5m) / TA 3.39b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of November 11, 2026, the stock is trading at USD 126.62 with a total of 673,099 shares traded. Over the past week, the price has changed by +0.06%, over one month by +0.08%, over three months by +1.23% and over the past year by +84.15%.
Current recommended Stop Loss: 126.00 (which is 0.5% or 3 ATR below the current price).
Integer Holdings has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold ITGR.
- StrongBuy: 0
- Buy: 0
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 127 | 0.3% |
P/E Trailing = 42.4698
P/E Forward = 22.4719
P/S = 2.3571
P/B = 2.4923
P/EG = 2.8099
Revenue TTM = 1.82b USD
EBIT TTM = 146.8m USD
EBITDA TTM = 286.2m USD
Long Term Debt = 1.22b USD (from longTermDebt, last quarter)
Short Term Debt = 8.36m USD (from shortTermDebt, last quarter)
Debt = 1.47b USD (from shortLongTermDebtTotal, last quarter) + Leases 125.3m
Net Debt = 1.46b USD (calculated: Debt 1.47b - CCE 14.1m)
Enterprise Value = 5.76b USD (4.30b + Debt 1.47b - CCE 14.1m)
Interest Coverage Ratio = 3.78 (Ebit TTM 146.8m / Interest Expense TTM 38.8m)
EV/FCF = 70.38x (Enterprise Value 5.76b / FCF TTM 81.8m)
FCF Yield = 1.42% (FCF TTM 81.8m / Enterprise Value 5.76b)
FCF Margin = 4.49% (FCF TTM 81.8m / Revenue TTM 1.82b)
Net Margin = 5.68% (Net Income TTM 103.7m / Revenue TTM 1.82b)
Gross Margin = 23.58% ((Revenue TTM 1.82b - Cost of Revenue TTM 1.39b) / Revenue TTM)
Gross Margin QoQ = 22.59% (prev 24.34%)
Tobins Q-Ratio = 1.70 (Enterprise Value 5.76b / Total Assets 3.39b)
Interest Expense / Debt = 2.64% (Interest Expense 38.8m / Debt 1.47b)
Taxrate = 3.95% (4.26m / 108.0m)
NOPAT = 141.0m (EBIT 146.8m * (1 - 3.95%))
Current Ratio = 3.98 (Total Current Assets 801.4m / Total Current Liabilities 201.1m)
Debt / Equity = 0.85 (Debt 1.47b / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = 5.09 (Net Debt 1.46b / EBITDA 286.2m)
Debt / FCF = 17.79 (Net Debt 1.46b / FCF TTM 81.8m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.05% (Net Income 103.7m / Total Assets 3.39b)
RoE = 6.02% (Net Income TTM 103.7m / Total Stockholder Equity 1.72b)
RoCE = 4.99% (EBIT 146.8m / Capital Employed (Equity 1.72b + L.T.Debt 1.22b))
RoIC = 4.42% (NOPAT 141.0m / Invested Capital 3.19b)
WACC = 6.47% (E(4.30b)/V(5.77b) * Re(7.82%) + D(1.47b)/V(5.77b) * Rd(2.64%) * (1-Tc(0.04)))
Discount Rate = 7.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.86 | Cagr: -1.17%
[DCF] Terminal Value 73.10% ; FCFF base≈97.6m ; Y1≈85.6m ; Y5≈69.2m
[DCF] Fair Price = N/A (negative equity: EV 1.11b - Net Debt 1.46b = -345.5m; debt exceeds intrinsic value)
EPS Correlation: 92.54 | EPS CAGR: 11.46% | SUE: -3.99 | # QB: -1
Revenue Correlation: 95.06 | Revenue CAGR: 6.29% | SUE: -0.95 | # QB: -1
EPS current Quarter (2027-03-31): EPS=1.55 | Chg30d=+2.49% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=5.60 | Chg30d=-9.13% | Revisions=+50% | GrowthEPS=-12.5% | GrowthRev=-2.2%
EPS next Year (2027-12-31): EPS=6.87 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+22.7% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +22% (up=4, down=2)